Holen Sie sich die Stockscreener-App
2.895
3.82%
-0.115
Schlusskurs vom Vortag:
$3.01
Offen:
$2.91
24-Stunden-Volumen:
185.21K
Relative Volume:
1.27
Marktkapitalisierung:
$20.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+28.95%
1M Leistung:
+51.57%
6M Leistung:
+44.75%
1J Leistung:
-44.54%
1-Tages-Spanne:
$2.80
$3.01
1-Wochen-Bereich:
$2.17
$3.265
52-Wochen-Spanne:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Vergleichen Sie TRAW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.95 | 21.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.80 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.19 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.04 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
806.95 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.71 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Will Traws Pharma Inc. stock benefit from green energy trendsJuly 2025 Momentum & Short-Term High Return Strategies - newser.com
Live market analysis of Traws Pharma Inc.July 2025 Market Mood & Precise Buy Zone Tips - newser.com
Technical signs of recovery in Traws Pharma Inc.July 2025 Big Picture & AI Optimized Trade Strategies - newser.com
Key metrics from Traws Pharma Inc.’s quarterly dataMarket Sentiment Review & Long-Term Growth Plans - newser.com
Tick level data insight on Traws Pharma Inc. volatilityJuly 2025 Update & Accurate Technical Buy Alerts - newser.com
Traws Pharma Appoints Dr. John Leaman to Board, Confirms CEO and CFO Roles - MyChesCo
Trend analysis for Traws Pharma Inc. this week2025 Short Interest & Real-Time Chart Pattern Alerts - newser.com
Ranking Traws Pharma Inc. among high performing stocks via tools2025 Market WrapUp & Growth Focused Stock Reports - newser.com
Why analysts recommend Traws Pharma Inc. (0T20) stock2025 Short Interest & Daily Profit Focused Screening - newser.com
Forecasting Traws Pharma Inc. price range with options dataJuly 2025 Outlook & Scalable Portfolio Growth Methods - newser.com
Is Traws Pharma Inc. (0T20) stock attractive post correction2025 Support & Resistance & Short-Term High Return Ideas - newser.com
Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer - MSN
Will Traws Pharma Inc. (0T20) stock extend growth storyEarnings Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Why Traws Pharma Inc. (0T20) stock is a must watch ticker2025 Historical Comparison & Risk Managed Trade Strategies - newser.com
Market reaction to Traws Pharma Inc.’s recent newsMarket Trend Summary & Daily Stock Trend Reports - newser.com
[DEF 14A] Traws Pharma, Inc. Definitive Proxy Statement - Stock Titan
Traws Pharma Inc 0T20 Stock Analysis and ForecastStock Price Forecasts & Free Get High Impact Recommendations - earlytimes.in
Traws Pharma Appoints New Independent Director and CEO - The Globe and Mail
Traws Pharma, Inc. Appoints Iain Dukes as Chief Executive Officer - MarketScreener
Traws Pharma, Inc. Appoints Charles Parker as Chief Financial Officer - MarketScreener
Reversal indicators forming on Traws Pharma Inc. stockTrade Performance Summary & AI Enhanced Trading Alerts - newser.com
Traws Pharma appoints John Leaman to board, removes interim tags from execs - Investing.com
Traws Pharma, Inc. Appoints John Leaman, MD, to Board of Directors and Officially Names Key Executives as CEO and CFO - Quiver Quantitative
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives - The Manila Times
Is Traws Pharma Inc. stock safe for conservative investors2025 Risk Factors & Reliable Breakout Forecasts - newser.com
D pipelineStock Surge & Reliable Momentum Entry Alerts - newser.com
Using fundamentals and technicals on Traws Pharma Inc.Trade Entry Summary & Weekly Setup with ROI Potential - newser.com
Using data tools to time your Traws Pharma Inc. exitChart Signals & Consistent Profit Alerts - newser.com
How Traws Pharma Inc. stock performs in rate cut cyclesQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-09-30 05:15:32 - newser.com
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Es liegen keine Finanzdaten für Traws Pharma Inc (TRAW) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):